Drugs in Development for Hepatitis B (June 2017)
Algolia Search
Schedule Telemedicine Consult with Dr. Gish Powered byTelemed2U
Powered byTelemed2U

Drugs in Development for Hepatitis B (June 2017)

Abstract: With high morbidity and mortality worldwide, there is great interest in effective therapies for chronic hepatitis B (CHB) virus. There are currently several dozen investigational agents being developed for treatment of CHB. They can be broadly divided into two categories: (1) direct-acting antivirals (DAAs) that interfere with a specific step in viral replication; and (2) host-targeting agents that inhibit viral replication by modifying host cell function, with the latter group further divided into the subcategories of immune modulators and agents that target other host functions. Included among the DAAs being developed are RNA interference therapies, covalently closed circular DNA (cccDNA) formation and transcription inhibitors, core/capsid inhibitors, reverse transcriptase ………

» View/Download Article